Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04225910 | Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer | unknown | Early Phase 1 | 20 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 13, 2020 | clinicaltrials |
| NCT03436342 | Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Dec 27, 2019 |
| clinicaltrials |
| NCT04191941 | Treatment of Hematological Malignancy With Novel CAR-T Cells. | unknown | Early Phase 1 | 9 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT03649529 | Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy | unknown | Early Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04186052 | Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04184414 | The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies | unknown | Early Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2019 | clinicaltrials |
| NCT04182581 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 18 | Xijing HospitalOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04169932 | The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04166838 | The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) | unknown | Early Phase 1 | 20 | Shanghai Longyao Biotechnology Inc., Ltd.OTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04156178 | CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156243 | CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156256 | CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies | unknown | Early Phase 1 | 20 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04156269 | BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 12 | iCell Gene TherapeuticsINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT04130750 | Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice | unknown | Early Phase 1 | 200 | Peking University People's HospitalOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT04113096 | Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer | unknown | Early Phase 1 | 104 | The University of The West IndiesOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT03940001 | A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer | unknown | Early Phase 1 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT03910842 | Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | unknown | Early Phase 1 | 12 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT04076137 | Targeted T-cell Therapy in Solid Tumors | unknown | Early Phase 1 | 10 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03116659 | CTCL Directed Therapy | unknown | Early Phase 1 | 8 | James J. Peters Veterans Affairs Medical CenterFED | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03965546 | ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | unknown | Early Phase 1 | 27 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04048317 | Effectiveness of Drug Eluting TACE in Primary HCC | unknown | Early Phase 1 | 75 | Assiut UniversityOTHER | 0 | Aug 7, 2019 | clinicaltrials |
| NCT04046185 | Programmed Death-1(PD-1) Inhibitor Combined With Progesterone Treatment in Endometrial Cancer(ECCT) | unknown | Early Phase 1 | 60 | Shanghai First Maternity and Infant HospitalOTHER | 0 | Aug 6, 2019 | clinicaltrials |
| NCT04041882 | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT03960788 | Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer | unknown | Early Phase 1 | 50 | University of CincinnatiOTHER | 1 | May 23, 2019 | clinicaltrials |
| NCT03799913 | MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer | unknown | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03822130 | Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer | unknown | Early Phase 1 | 150 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03690310 | Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03692637 | Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer | unknown | Early Phase 1 | 30 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03824951 | Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 10 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03824964 | Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 10 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 31, 2019 | clinicaltrials |
| NCT03825731 | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | unknown | Early Phase 1 | 20 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03692767 | Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03815084 | A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors | unknown | Early Phase 1 | 100 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03815630 | A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors(DC-CIK) | unknown | Early Phase 1 | 100 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03672305 | Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC | unknown | Early Phase 1 | 50 | The Second Hospital of Nanjing Medical UniversityOTHER | 0 | Sep 18, 2018 | clinicaltrials |
| NCT03661554 | BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma(BCMA CAR-T) | unknown | Early Phase 1 | 15 | The Pregene (ShenZhen) Biotechnology Company, Ltd.INDUSTRY | 1 | Sep 10, 2018 | clinicaltrials |
| NCT03559764 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Early Phase 1 | 20 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jun 18, 2018 | clinicaltrials |
| NCT03497819 | Autologous CARTmeso/19 Against Pancreatic Cancer | unknown | Early Phase 1 | 10 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 13, 2018 | clinicaltrials |
| NCT03245554 | Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol | unknown | Early Phase 1 | 80 | Central South UniversityOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02910804 | IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma | unknown | Early Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03385148 | The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients | unknown | Early Phase 1 | 70 | Xijing HospitalOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT03228303 | Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia | unknown | Early Phase 1 | 100 | Assiut UniversityOTHER | 0 | Oct 10, 2017 | clinicaltrials |
| NCT02691169 | Integrated 18F-labelled PSMA Project | unknown | Early Phase 1 | 10 | St. Joseph's Healthcare HamiltonOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT03288298 | Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line | unknown | Early Phase 1 | 4 | Cairo UniversityOTHER | 0 | Sep 20, 2017 | clinicaltrials |
| NCT03267173 | Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | unknown | Early Phase 1 | 10 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT03070613 | Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery | unknown | Early Phase 1 | 50 | University of OxfordOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT03214939 | Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer | unknown | Early Phase 1 | 30 | Research Institute of Fundamental and Clinical ImmunologyOTHER_GOV | 1 | Jul 12, 2017 | clinicaltrials |
| NCT03113019 | Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer(BC-LDC) | unknown | Early Phase 1 | 26 | Research Institute of Fundamental and Clinical ImmunologyOTHER_GOV | 0 | Apr 13, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jan 13, 2020source: clinicaltrials